The B Cell Antigen Receptor Controls Integrin Activity through Btk and PLCγ2
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Integrin-mediated adhesion and B cell antigen receptor (BCR) signaling play a critical role in B cell development and function, including antigen-specific B cell differentiation. Here we show that the BCR controls integrin α4β1 (VLA-4)-mediated adhesion of B cells to vascular cell adhesion molecule-1 and fibronectin. Molecular dissection of the underlying signaling mechanism by a combined biochemical, pharmacological, and genetic approach demonstrates that this BCR-controlled integrin-mediated adhesion requires the (consecutive) activation of Lyn, Syk, phosphatidylinositol 3-kinase, Bruton's tyrosine kinase (Btk), phospholipase C (PLC)γ2, IP3R-mediated Ca2+ release, and PKC. In contrast, activation of mitogen-activated protein kinase kinase (MEK) or extracellular signal–regulated kinase (ERK) is not required, and simultaneous activation of MEK, ERK, and PKB is not sufficient either. Furthermore, Btk is also involved in the control of integrin-mediated adhesion of preB cells. The control of integrin α4β1-mediated B cell adhesion by the BCR involves cytoskeletal reorganization and integrin clustering. These results reveal a novel function for the BCR and Btk, i.e., regulation of integrin α4β1 activity, thereby providing new insights into the control of B cell development and differentiation, as well as into the pathogenesis of the immunodeficiency disease X-linked agammaglobulineamia (XLA).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Hashimoto, A., Okada, H., Jiang, A., Kurosaki, M., Greenberg, S., Clark, E. A., & Kurosaki, T. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.7.1287 · Cited by 199
Cited by
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509388 · Cited by 1,583
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Self-citationPonader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Okada, T., Miller, M. J., Parker, I., Krummel, M. F., Neighbors, M., Hartley, S. B., O'Garra, A., Cahalan, M. D., & Cyster, J. G. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030150 · Cited by 585
de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 554
Self-citationTargeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Self-citationTargeting B cell receptor signalling in cancer: preclinical and clinical advances
Burger, J. A., & Wiestner, A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.121 · Cited by 431
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
B cell receptor signaling in chronic lymphocytic leukemia
Burger, J. A., & Chiorazzi, N. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.002 · Cited by 327
Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia
Kamphuis, E., Junt, T., Waibler, Z., Forster, R., & Kalinke, U. (2006) · Blood · doi:10.1182/blood-2006-06-027599 · Cited by 306
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature Reviews Immunology · doi:10.1038/nri3487 · Cited by 288
de Gorter, D. J. J., Beuling, E. A., Kersseboom, R., Middendorp, S., van Gils, J. M., Hendriks, R. W., Pals, S. T., & Spaargaren, M. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.012 · Cited by 285
Self-citationBurger, J. A., & Gribben, J. G. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.011 · Cited by 285
Visualizing B cell capture of cognate antigen from follicular dendritic cells
Suzuki, K., Grigorova, I., Phan, T. G., Kelly, L. M., & Cyster, J. G. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090209 · Cited by 271
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Arana, E., Vehlow, A., Harwood, N. E., Vigorito, E., Henderson, R., Turner, M., Tybulewicz, V. L. J., & Batista, F. D. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.003 · Cited by 156
“…very late antigen-4 (VLA-4) requires the consecutive activation of the tyrosine kinases Lyn and Syk, phosphoinositide-3 kinase (PI3K), Bruton’s tyrosine kinase, phospholipase Cg2, protein kinase C, and inositol 1,4,5-trisphosphate (IP3)-receptor-mediated calcium release (Spaargaren et al., 2003).”
BackgroundResultTissino, E., Benedetti, D., Herman, S. E. M., ten Hacken, E., Ahn, I. E., Chaffee, K. G., Rossi, F. M., Dal Bo, M., Bulian, P., Bomben, R., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171288 · Cited by 92
“1 H), reflecting higher levels of avidity to the ligand (Spaargaren et al., 2003).”
BackgroundResultInfluentialStephens, D. M., & Byrd, J. C. (2021) · Blood · doi:10.1182/blood.2020006783 · Cited by 37
Rac-mediated stimulation of phospholipase Cγ2 amplifies B cell receptor-induced calcium signaling
Walliser, C., Tron, K., Clauss, K., Gutman, O., Kobitski, A. Y., Retlich, M., Schade, A., Röcker, C., Henis, Y. I., Nienhaus, G. U., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.645739 · Cited by 21
“at the immunological synapse, may give rise to locally enhanced Rac activation, allowing for an increased potency of BCR ligand to mediate integrin activation, at least in part by enhanced activity of PLC 2 (73, 77).”
Background
Metadata
- Authors
- Spaargaren, M., Beuling, E. A., Rurup, M. L., Meijer, H. P., Klok, M. D., Middendorp, S., Hendriks, R. W., & Pals, S. T.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-11-10
- Volume
- 198
- Issue
- 10
- Pages
- 1539-1550
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2171644620
- Cited by
- 228
- References
- 2
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.